Open Access
| Numéro |
Radioprotection
Volume 60, Numéro 1, January-March 2025
|
|
|---|---|---|
| Page(s) | 91 - 98 | |
| DOI | https://doi.org/10.1051/radiopro/2024042 | |
| Publié en ligne | 14 mars 2025 | |
- Barquero R, Basurto F, Nunez C, et al. 2008. Liquid discharges from patients undergoing 131I treatments. J Environ Radioact 99: 1530–1534. [CrossRef] [PubMed] [Google Scholar]
- China Atomic Energy Agency, Ministry of Science and Technology, Ministry of Ecology and Environment et al.2021. Medium and long-term development plan for medical isotopes. Available from: https://www.caea.gov.cn/n6760338/n6760342/c6831058/content.html. [Google Scholar]
- Clarke SEM. 1994. Radioiodine therapy of the thyroid. In Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment pp. 833-845. Edinburgh: Churchill Livingstone. [Google Scholar]
- Department of Radiation Source Safety Regulation, Ministry of Ecology and Environment. 2023. Reply to Consultation on Several Clauses of the Nuclear Medicine Standard (Radiation Notice (2023) 20th). Available from: https://www.mee.gov.cn/xxgk2018/xxgk/sthjbsh/202309/t20230913_1040761.html [Reply to Consultation on Several Clauses of the Nuclear Medicine Standard]. [Google Scholar]
- Driver I, Packer S. 2001. Radioactive waste discharge quantities for patients undergoing radioactive iodine therapy for thyroid carcinoma. Nucl Med Commun 22: 1129. [CrossRef] [PubMed] [Google Scholar]
- Esser JP, Krenning EP, Teunissen JJM, et al. 2006. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Molec Imag 33: 1346–1351. [CrossRef] [PubMed] [Google Scholar]
- General Administration of Quality Supervision, Inspection and Quarantine of the People’s Republic of China.2002. Basic standards for protection against ionizing radiation and for the safety of radiation sources: GB 18871. Beijing: Standards Press of China. [Google Scholar]
- State Bureau of Environment Protection, General Administration of Quality Supervision, Inspection and Quarantine. 2005. Discharge Standard of water pollutants for medical organization: GB 18846. Beijing: Standards Press of China. [Google Scholar]
- ICRP.1991. Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. Oxford: Pergamon Press. [Google Scholar]
- ICRP. 2004. Release of Patients after Therapy with Unsealed Radionuclides. Ann. ICRP 34. DOI: 10.1016/j.icrp.2004.08.001 [Google Scholar]
- International Atomic Energy Agency, Pan American Health Organization, World Health Organization. 2002. Radiological Protection for Medical Exposure to Ionizing Radiation: IAEA Safety Standards Series No. RS-G-1. 5. Vienna:International Atomic Energy Agency. [Google Scholar]
- Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP. 2001. [177Lu-DOTA0, Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 28: 1319–1325. [CrossRef] [PubMed] [Google Scholar]
- Levart D, Kalogianni E, Corcoran B, et al. 2019. Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours. EJNMMI Phys 6: 7–7. [CrossRef] [PubMed] [Google Scholar]
- Ministry of Ecology and Environment of the People’s Republic of China. 2021. Radiation Protection and Safety Requirements for Nuclear Medicine: HJ 1188—2021. Beijing: Environmental Science Press. [Google Scholar]
- US Nuclear Regulatory Commission. 1997. Regulatory Guide 8. 39, Release of Patients Administered Radioactive Materials. Washington, DC: US Government Printing Office. [Google Scholar]
- Ward WF. 2006. Basic principles of radiation biology. In: Henkin R. E., Bova D., Dillehay G. L. et al. (Eds.) Nuclear Medicine pp. 507-522. Philadelphia: MOSBY ELSEVIER. [Google Scholar]
- Wyszomirska A. 2012. Iodine-131 for therapy of thyroid diseases. Physical and biological basis. Nuclear Medicine Review for Central and Eastern Europe 15: 120–123. [Google Scholar]
- Zaknun JJ, Bodei L,Mueller-Brand J et al. 2013. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Molec Imag 40: 800–816. [CrossRef] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.